Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases
Open Access
- 8 December 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e114404
Abstract
Combined intra-operative ablation and resection (CARe) is proposed to treat extensive colorectal liver metastases (CLM). This multicenter study was conducted to evaluate overall survival (OS), local recurrence-free survival (LRFS), hepatic recurrence-free survival (HRFS) and progression-free survival (PFS), to identify factors associated with survival, and to report complications. Four centers combined retropectively their clinical experiences regarding CLM treated by CARe. CLM characteristics, pre- and post-operative chemotherapy regimens, surgical procedures, complications and survivals were analyzed. Of the 288 patients who received CARe, 210 (73%) had synchronous and 255 (88%) had bilateral CLM. Twenty-two patients (8%) had extrahepatic disease. Median follow-up was 3.17 years (95%CI 2.83–4.08). Median OS was 3.33 years (95%CI 3.08–4.17) and 5-year OS was 37% (95%CI 29–45). One- and 5-year LRFS from ablated lesions were 87.9% (95%CI 83.3–91.2) and 78.0% (95%CI 71–83), respectively. Median HRFS and PFS were 14 months (95%CI 11–18) and 9 months (95%CI 8–11), respectively. One hundred patients experienced complications: 29 grade I, 68 grade II–III–IV, and three deaths. In the multivariate models adjusted for center, the occurrence of complications was confirmed as a major independent factor associated with 3-year OS (HR 1.80; P = 0.008). Five-year OS was 25.6% (95%CI 14.9–37.6) for patients with complications and 45% (95%CI 33.3–53.4) for patients without. Recent strategies facing advanced CLM include non-anatomic resections, portal-induced hypertrophy of the future remnant liver and aggressive medical preoperative treatments. CARe has the qualities of an approach that allows effective tumor clearance while maintaining good tolerance for the patient.Keywords
This publication has 30 references indexed in Scilit:
- Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection (Br J Surg 2012; 99: 558–565)British Journal of Surgery, 2012
- Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection19British Journal of Surgery, 2012
- Unravelling the complexity of metastasis — molecular understanding and targeted therapiesNature Reviews Cancer, 2011
- High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define OutcomeJournal of Clinical Oncology, 2011
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialThe Lancet Oncology, 2010
- Guidelines for resection of colorectal cancer liver metastasesGut, 2006
- Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver MetastasesAnnals of Surgery, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastasesJournal of Gastrointestinal Surgery, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958